Oragenics Announces Approval to Initiate Phase 2 Concussion Drug Trial
Oragenics, Inc. recently announced it has received approval from the Human Research Ethics Committee (HREC) in Australia to initiate its Phase 2 clinical trial evaluating ONP-002, the company’s proprietary neuroprotective therapy, for the treatment of mild traumatic brain injury (mTBI), aka concussion.
This approval marks a significant milestone in expanding Oragenics’ clinical development efforts internationally. With this clearance, Oragenics can initiate clinical trials in Australia and could begin patient enrollment as early as the second quarter of 2025. Once the company is prepared to commence enrollment, patient enrollment and treatment administration is expected to occur in level 1 trauma emergency departments where concussed patients are often seen following motor vehicle accidents, falls, and contact sports
“Receiving HREC approval in Australia brings us one step closer to offering a much-needed therapeutic option for patients suffering from concussions,” said Janet Huffman, Chief Executive Officer of Oragenics. “With enrollment sites considered in both Australia and New Zealand, we are significantly expanding the geographic footprint of our ONP-002 program as we move this critical drug trial forward.”
ONP-002 is designed for intranasal administration, offering a non-invasive and efficient route for drug delivery to the brain. In preclinical models, ONP-002 has demonstrated the ability to reduce inflammation, oxidative stress, and brain swelling associated with concussion. A Phase I clinical trial showed ONP-002 to be safe and well-tolerated. ONP-002 is being positioned as a promising potential acute therapy for this widespread condition.
Oragenics is a biotechnology company focused on developing intranasal therapeutics for neurological disorders, including its lead candidate, ONP-002, for the treatment of mild traumatic brain injury (mTBI) or concussion. The Company is also advancing proprietary powder formulations and intranasal delivery technology to enhance drug administration. For more information, visit www.oragenics.com.
Total Page Views: 233
